Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
290 results about "Polymorphonuclear granulocyte" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Granulocytes are a category of white blood cells characterized by the presence of granules in their cytoplasm. They are also called polymorphonuclear leukocytes (PMN, PML, or PMNL) because of the varying shapes of the nucleus, which is usually lobed into three segments.
Transfection of blood cells with mRNA for immune stimulation and gene therapy
InactiveUS20060188490A1Improve stabilityIncrease transfectionSsRNA viruses negative-senseBiocideAntigenCancer prevention
The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and / or blood platelets, in combination with a pharmaceutically acceptable excipient and / or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and / or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.
Owner:CUREVAC AG
Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype
InactiveUS6498148B1Treatment and prevention of inflammationSuppresses antigen-stimulated granulocyte infiltrationOrganic active ingredientsSenses disorderAntigen stimulationTherapeutic intent
The invention relates to methods for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation in tissue of an antigen-sensitized mammal host by delivering an immunostimulatory oligonucleotide to the host. In addition, methods for using the immunostimulatory oligonucleotides to boost a mammal host's immune responsiveness to a sensitizing antigen (without immunization of the host by the antigen) and shifting the host's immune responsiveness to a Th1 phenotype to achieve various therapeutic ends are provided. Kits for practicing the methods of the invention are also provided.
Owner:RGT UNIV OF CALIFORNIA
Devices and methods for inhibiting granulocyte activation by neural stimulation
Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Methods and compositions for the differentiation of stem cells
ActiveUS20100216181A1Overcome limitationsPromote cell differentiationMicrobiological testing/measurementCulture processProgenitorInduced pluripotent stem cell
The present invention provides methods and compositions for the production of hematopoietic progenitor cells or endothelial progenitor cells from human pluripotent stem cells using a defined cell culture medium without the need to utilize feeder cells or serum. In some embodiments, differentiation is accomplished using hypoxic atmospheric conditions. The defined medium of the present invention may contain growth factors and a matrix component. The hematopoietic progenitor cells may be further differentiated into cell lineages including red blood cells, macrophages, granulocytes, and megakaryocytes. The endothelial progenitor cells may be further differentiated into endothelial cells. Also disclosed are screening assays for identification of candidate substances that affect differentiation of pluripotent stem cells into progenitor cells.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
The invention provides methods and compositions for targeting a separately generated immune response to a specific organ or tissue, e.g. one affected by cancer, using one or more agents with a tropism for the organ or tissue or that can be specifically localized to the desired organ or tissue. For example, the invention provides methods ands compositions for treating liver metastases from colorectal cancer using a combination of a granulocyte / macrophage colony stimulating factor (GM-CSF) augmented tumor cell vaccination and Listeria monocytogenes (LM) infection.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Devices and methods for inhibiting granulocyte activation by neural stimulation
ActiveUS20090062874A1Inhibition of activationSufficient amountElectrotherapyDevices using mechanical vibrationsGranulocyte activationMedicine
Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20130150559A1Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionDc maturation
Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:NOVO NORDISK AS
Liquid Formulation of G-CSF Conjugate
ActiveUS20090143292A1Prevents acid hydrolysisImprove solution stabilityPeptide/protein ingredientsPharmaceutical delivery mechanismG-csf therapySuccinic acid
The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and / or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.
Owner:RATIOPHARM GMBH
Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood
This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and / or NK cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.
Owner:BIONEER +1
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS8231878B2Strong upregulationImmunoglobulin superfamilyPeptide/protein ingredientsDc maturationAutoimmune disease
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COSMO TECH LTD
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20100310560A1Strong upregulationOrganic active ingredientsImmunoglobulin superfamilyAutoimmune responsesDc maturation
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COSMO TECH LTD
Absorbent and Column for Extracorporeal Circulation
InactiveUS20090275874A1Prolong lifeImprove the quality of lifeSemi-permeable membranesHaemofiltrationExtracorporeal circulationZeta potential
The present invention provides an absorbent which can remove cells present in blood including activated leukocytes such as granulocytes and monocytes, and cancer cells as well as can remove cytokines which facilitate the activation of the remaining cells, and further has no concern for pressure loss and has high configuration stability. That is, the present invention provides an absorbent which absorbs the granulocytes and the monocytes in blood, an absorbent for cancer therapy which absorbs an immunosuppressive protein and an absorbent having a bilayer structure of a net and a nonwoven fabric, having a zeta potential of −20 mV or more, as well as a blood circulation column containing any of the absorbents filled therein.
Owner:TORAY IND INC
Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha
The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and / or physiologically compatible salts thereof which can be produced therefrom and / or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and / or TNFα-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
![Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha](https://images-eureka.patsnap.com/patent_img/6b070c20-5975-4f0b-9ddd-c22a4a4e5553/US20080160028A1-20080703-D00000.png "Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha")
![Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha](https://images-eureka.patsnap.com/patent_img/6b070c20-5975-4f0b-9ddd-c22a4a4e5553/US20080160028A1-20080703-D00001.png "Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha")
![Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha](https://images-eureka.patsnap.com/patent_img/6b070c20-5975-4f0b-9ddd-c22a4a4e5553/US20080160028A1-20080703-C00001.png "Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha")
Owner:THE MEDICINES CO (LEIPZIG) GMBH
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS8981061B2Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsDc maturationApoptosis
Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:NOVO NORDISK AS
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20090081199A1Strong upregulationOrganic active ingredientsCompound screeningApoptosisAutoimmune disease
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:BIOXELL
Method of classifying and counting leucocytes
ActiveUS20080176274A1Low costAccurate classificationMicrobiological testing/measurementIndividual particle analysisStainingWhite blood cell
Owner:SYSMEX CORP
Glycosylated G-CSF
InactiveUS20070243165A1Altered phenotypeVirusesPeptide/protein ingredientsG-csf therapyEvolutionary biology
Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns.
Owner:GEORGIA RESERACH FOUND INC UNIV OF +1
Liquid formulation of G-CSF conjugate
ActiveUS8207112B2Prevents acid hydrolysisImprove solution stabilityPeptide/protein ingredientsPharmaceutical delivery mechanismSuccinic acidG-csf therapy
Owner:RATIOPHARM GMBH
Quantitative determination method for activity of nerve growth factor
The invention discloses a quantitative determination method for activity of a nerve growth factor. The method comprises the following steps of: (1) washing TF-1 cells in a logarithmic phase by a basal culture medium that contains no serum and recombined human granulocyte-macrophage colony stimulating factors, and then resuspending the TF-1 cells to obtain TF-1cell suspension liquid; (2) respectively adding the TF-1cell suspension liquid into a gradient-diluted nerve growth factor standard sample and a sample to be tested, and incubating at 37 DEG C in presence of 5% of CO2; then respectively adding an indicating agent to detect the absorbance / fluorescence value and drawing a standard curve line; and (3) calculating the activity concentration of the nerve growth factor of the sample to be tested according to the standard curve line and the absorbance / fluorescence value of the sample. The quantitative determination method for activity of the nerve growth factor disclosed by the invention has good accuracy and precision.
Owner:STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD
Leukocyte classified counting reagent, kit and preparation method thereof and method of leukocyte classified counting
ActiveCN101988082AWide variety of sourcesRapid and complete biodegradationMicrobiological testing/measurementScattering properties measurementsCyanineShortest distance
The invention discloses a leukocyte classified counting reagent, which includes: (1) cyanine type fluorescent dye; (2) glucoside compound. The invention further discloses a kit containing the leukocyte classified counting reagent and a preparation method thereof. The invention also discloses the reagent and a method f leukocyte classified counting for the kit. With the reagent, the kit and the method disclosed in the invention, the leukocyte can be counted in classification, wherein each subclass of the leukocyte has high discrimination index and good discrimination effect, and particularly, problems of difficulty in distinguishing a lymphocyte from a mononuclear cell and too short distance between an acidophilic cell and a neutrophile granulocyte are solved.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20050260670A1Strong upregulationAntibacterial agentsAntimycoticsAutoimmune diseaseApoptosis
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-beta. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:COLONNA MARCO +1
System for purifying certain cell populations in blood or bone marrow by depleting others
ActiveUS8747289B2Improve isolationSimple processOther blood circulation devicesPreparing sample for investigationRed blood cellStromal vascular fraction
Owner:THERMOGENESIS
Granulocyte Adsorbent
InactiveUS20080021365A1High granulocyte-separating efficiencyEffectively and selectively removedOther blood circulation devicesSolvent extractionSorbentBody fluid
This invention relates to a granulocyte adsorbent comprising a polymer compound having an unsubstituted hydroxyl group and a hydroxyl group in which H has been substituted with at least one substituent R, a method for producing such adsorbent, a device for adsorbing granulocytes and a system for removing granulocytes using such adsorbent, and body fluid or a cell suspension from which granulocytes have been removed using such adsorbent.
Owner:KANEKA CORP
Method and composition for altering a B cell mediated pathology
InactiveUS20050238645A1BiocidePeptide/protein ingredientsAntibody AffinitiesKeyhole-limpet haemocyanin
The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and / or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and / or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprise chimeric proteins made specifically from particular B cells from a patient having B cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a B cell mediated pathology.
Owner:MMRGLOBAL
Linear array SAR (Synthetic Aperture Radar) three-dimensional imaging method based on threshold gradient tracking algorithm
ActiveCN107037429AImproving Sparse Imaging PerformanceRadio wave reradiation/reflectionSynthetic aperture sonarTotal blood
The invention provides a linear array SAR (Synthetic Aperture Radar) three-dimensional imaging method based on a threshold gradient tracking algorithm. The method comprises the steps of establishing a linear measurement model between linear array SAR original echo signals and a three-dimensional observation scene target scattering coefficient using a correlation among linear array SAR system parameters, motion platform parameters, space parameters of an observation scene target and original echo signals, and then reconstructing the observation scene target scattering coefficient using a TBGP (Total Blood Granulocyte Pool) method based on the signal linear measurement model. By using the contrast of maximum and minimum target scattering coefficients and the change rate of the target scattering coefficient as algorithm iteration termination conditions, the linear array SAR sparse imaging performance of a GP (Genetic Programming) algorithm under the condition that the sparsity of the observation scene is unknown is improved, the operation efficiency and the space storage efficiency are improved relative to an OMP (Orthogonal Matching Pursuit) algorithm, and the method can be applied in the fields of synthetic aperture radar imaging, earth remote sensing and the like.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA
Method for differential counting of white blood cells based on morphology
InactiveCN103345654AAccurate classificationAvoid subjective factorsCharacter and pattern recognitionIndividual particle analysisExtinctionWhite blood cell
The invention discloses a method for differential counting of white blood cells based on morphology. The method includes the steps that after Wright stain is conducted on peripheral blood smears, a microscope is used for collecting an image; after the image is processed by a computer system, morphology parameter analysis is conducted on the white blood cells, and the white blood cells are divided into a lymphocyte area, a monocyte area, a granulocyte area and a cell extinction area; the morphology parameter analysis is conducted on the area cells which are divided in the previous step, and the cells are further divided into monocytes, lymphocytes, eosinophilic granulocytes and neutrophile granulocytes precisely; the differential counting statistics are carried out on the variety of the divided cells. The computer system is used for analyzing the processed image, several simple morphology parameters are used for making a two-dimensional scatter diagram, all the cells are presented in a statistical diagram mode, the white blood cells can be classified rapidly and precisely, white blood cell counting is automatic, compared with manual counting, the procedures are simple and fast, the diagnose speed is greatly increased, and accuracy is improved substantially.
Owner:SUZHOU CHUANGJI BIOLOGICAL TECH
Endothelial-targeted Adenoviral Vectors, Methods and Uses Therefor
InactiveUS20170159072A9Stimulate bone resorptionEnhanced bone resorptionVectorsPeptide/protein ingredientsCancer cellBinding peptide
Disclosed are adenovirus vectors comprising a ROBO4 enhancer / promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer promoter operatively linked to a transgene. Also disclosed are methods of expressing a transgene in an endothelial cell in vivo, comprising administering to a mammal an adenovirus comprising a ROBO4 enhancer / promoter operatively linked to a transgene. Also disclosed are uses of the adenoviral vectors, including mobilization of granulocytes, monocytes and lymphocytes from bone marrow, mobilization of cancer cells in vivo, selective targeting of endothelial cells, and cancer treatment methods.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Hematology reference control containing an immature granulocyte component
A hematology reference control containing an immature granulocyte component and the method of making are disclosed. The reference control includes an immature granulocyte component made of processed blood cells for simulating human immature granulocytes, and a suspension medium suitable for delivering the component to a blood analyzer for measurement of immature granulocytes. The immature granulocyte component can be made of processed avian, reptile or fish red blood cells, or human immature granulocytes produced in vitro. The reference control further includes a white blood cell component which includes white blood cell sub-components for simulating white blood subpopulations. Further disclosed is the method of using the reference control for measurement of immature granulocytes on a blood analyzer.
Owner:BECKMAN COULTER INC
Fc fusion protein of human granulocyte colony stimulin with enhanced bioactivity
InactiveCN1410450AImprove biological activityAntibody mimetics/scaffoldsColony-stimulating factorHalf-lifePharmacodynamic Study
Owner:PHARMAB
Combined reagent for detecting acute myelocytic leukemia cells and system thereof
ActiveCN109655616AWide coverageThere is no problem of reciprocal inhibition of expressionMaterial analysisCD33CD15
The invention relates to a combined reagent for detecting acute myelocytic leukemia cells and a system thereof, wherein the combined reagent and the system thereof belong to the field of medical technology. The combined reagent comprises at least one selected from the following antibody combinations: a first antibody combination which comprises CD38, CD13, CD34, CD117, CD33, CD19, HLA-DR and CD45antibodies; a second antibody combination which comprises CD38, CD64, CD34, CD123, CD56, CD14, HLA-DR and CD45 antibodies; and a third antibody combination which comprises CD38, CD7, CD34, CD5, CD11b,CD15 and CD45 antibodies. The antibody combinations of the invention cover the expression marks of three systems of granulocyte, single cell and lymphocyte. A normal antibody expression mode is established. Tumor cells can be identified maximally. Furthermore, through a large number of experiment data, the antibodies in each combination have no problem of mutual expression inhibition. FurthermoreAML-MRD can be comprehensively and quickly detected with high sensitivity through multi-parameter flow type cell analysis.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com